To receive all of Acticor Biotech’s financial information in real time, send a request by email to [email protected]
Thanks to a partnership between the University of Birmingham and Acticor Biotech, heart attack patients will be treated for the first time with glenzocimab, a promising new class of drugs.
This new drug likely to improve the long-term living conditions of patients who have suffered a myocardial infarction will be tested in the United Kingdom.
Following the signing of a partnership between the University of Birmingham and Acticor Biotech, a new clinical trial called LIBERATE will take place at two acute care hospitals in the UK: Queen Elizabeth Hospital, Birmingham and Northern General Hospital, in Sheffield.